- Conditions
- Healthy Volunteers
- Interventions
- 2-HOBA
- Dietary Supplement
- Lead sponsor
- Metabolic Technologies Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy Adults
- Interventions
- 2-HOBA
- Dietary Supplement
- Lead sponsor
- Metabolic Technologies Inc.
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Healthy Volunteers
- Interventions
- 2-HOBA, Placebo
- Dietary Supplement
- Lead sponsor
- Metabolic Technologies Inc.
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Older Adults
- Interventions
- 2-HOBA, Placebo
- Dietary Supplement
- Lead sponsor
- Metabolic Technologies Inc.
- Industry
- Eligibility
- 55 Years to 79 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Familial Hypercholesterolemia
- Interventions
- 2-Hydroxybenzylamine, Placebo
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Hyperlipidemia, Elevated Lp(a)
- Interventions
- 2-HOBA (Hobamine)
- Dietary Supplement
- Lead sponsor
- The Miriam Hospital
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- 2-hydroxybenzylamine acetate, Placebo
- Drug · Other
- Lead sponsor
- MTI Biotech Inc
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS), SARS CoV 2 Infection, Long COVID19
- Interventions
- To Measure levels of circulating monocyte/ T cell doublets at Baseline, To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment, To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment, To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA, To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo, To Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA, To Measure Orthostatic Tachycardia after 28 days of Treatment with Placebo
- Drug · Diagnostic Test
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Atrial Fibrillation
- Interventions
- 2-Hydroxybenzylamine, Placebo
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 22 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Salt Sensitivity of Blood Pressure, High Blood Pressure, Inflammation, Renin-Angiotensin-Aldosterone System
- Interventions
- 2-hydroxybenzylamine, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Systemic Lupus Erthematosus (SLE)
- Interventions
- 2-HOBA acetate (2-Hydroxybenzlamine acetate), Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Rheumatoid Arthritis
- Interventions
- 2-HOBA, Placebo
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee